SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Stake in Iterum Therapeutics plc

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Iterum Therapeutics plc, holding 1,445,158 ordinary shares as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Iterum Therapeutics plc.
• The Reporting Persons beneficially own an aggregate of 1,445,158 ordinary shares of Iterum Therapeutics plc.
• This ownership represents 4.99% of the company's ordinary shares outstanding.
• The percentage is calculated based on 28,961,084 shares outstanding as of November 4, 2024, as reported in Iterum Therapeutics plc's Form 10-K filed on November 14, 2024.
• Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of these shares.
• Steven Boyd is the managing member of Armistice Capital, LLC and is deemed to beneficially own the shares held by the Master Fund.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Iterum Therapeutics plc.

Sentiment

Score: 6

Explanation: The filing indicates a significant, albeit passive, institutional investment in Iterum Therapeutics plc, which can be viewed positively as a vote of confidence from a sophisticated investor. However, it does not contain new operational or financial news from the company itself, limiting its direct impact on sentiment.

Positives

• A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, have taken a substantial position in Iterum Therapeutics plc, indicating investor interest.
• The stake is held for investment purposes in the ordinary course of business, not for control, suggesting a passive investment strategy that avoids potential disruptive activist actions.

Negatives

• The filing itself does not contain negative information, as it is a standard disclosure of beneficial ownership.

Risks

• The document itself does not detail specific risks related to Iterum Therapeutics plc's operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

The document does not contain forward-looking statements or guidance from Iterum Therapeutics plc, as it is a disclosure of beneficial ownership by external parties.

Management Comments

• The filing is a disclosure by Armistice Capital, LLC and Steven Boyd, and does not contain direct comments or statements from Iterum Therapeutics plc's management.

Industry Context

This filing indicates continued institutional investor interest in the pharmaceutical/biotechnology sector, specifically in Iterum Therapeutics plc. Such Schedule 13G filings are common for investment funds taking passive stakes in public companies, providing transparency on significant ownership positions.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for beneficial ownership below 5% and does not provide specific performance metrics for comparison to industry standards or competitors.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially signaling confidence in the company's long-term prospects.
• Management: Awareness of a notable passive investor on their shareholder register, which can influence strategic considerations.

Next Steps

• The document does not outline specific future actions or milestones for Iterum Therapeutics plc. The Reporting Persons would file another amendment if their beneficial ownership percentage changes significantly (e.g., crosses a 1% threshold or exceeds 5%).

Key Dates

Recommendation

Keywords

Iterum Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, ordinary shares, investment, institutional investor, pharmaceutical, biotech